CD274 and lung cancer: Although immune checkpoint inhibitors (ICIs) have markedly improved first‐line management of non‐small cell lung cancer (NSCLC), many tumors eventually escape control after anti‐PD‐(L)1 therapy, leaving a clear therapeutic gap.